Summit Financial LLC Reduces Stock Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Posted by Ethan Ryder on Apr 3rd, 2025

Summit Financial LLC reduced its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 3.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,382 shares of the exchange traded fund’s stock after selling 248 shares during the quarter. Summit Financial LLC’s holdings in SPDR S&P Biotech ETF were worth $575,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Alliancebernstein L.P. purchased a new stake in SPDR S&P Biotech ETF in the 4th quarter worth about $607,000. Edmond DE Rothschild Holding S.A. increased its stake in shares of SPDR S&P Biotech ETF by 21.9% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 3,288 shares of the exchange traded fund’s stock worth $296,000 after purchasing an additional 590 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of SPDR S&P Biotech ETF by 24.1% in the fourth quarter. Wellington Management Group LLP now owns 65,250 shares of the exchange traded fund’s stock worth $5,876,000 after purchasing an additional 12,689 shares in the last quarter. O Shaughnessy Asset Management LLC raised its position in shares of SPDR S&P Biotech ETF by 38.6% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 718 shares of the exchange traded fund’s stock valued at $65,000 after purchasing an additional 200 shares during the period. Finally, Clearbridge Investments LLC lifted its stake in shares of SPDR S&P Biotech ETF by 20.5% during the 4th quarter. Clearbridge Investments LLC now owns 571,664 shares of the exchange traded fund’s stock valued at $51,484,000 after buying an additional 97,401 shares in the last quarter.

SPDR S&P Biotech ETF Trading Up 3.1 %

SPDR S&P Biotech ETF stock opened at $80.59 on Thursday. The firm has a 50 day simple moving average of $88.81 and a 200 day simple moving average of $93.53. SPDR S&P Biotech ETF has a 1-year low of $77.26 and a 1-year high of $105.47. The firm has a market capitalization of $5.08 billion, a price-to-earnings ratio of 11.47 and a beta of 1.00.

SPDR S&P Biotech ETF Cuts Dividend

The business also recently disclosed a dividend, which was paid on Wednesday, March 26th. Investors of record on Monday, March 24th were paid a dividend of $0.0053 per share. The ex-dividend date was Monday, March 24th.

SPDR S&P Biotech ETF Company Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.